BTK and malignant colon neoplasm: Moreover, our results demonstrating that BTK is a potent oncoprotein acting downstream of the RAS/ERK pathway, together with those showing that its inhibition profoundly affects colon cancer cells proliferation and survival, suggest that p65BTK might be a novel promising therapeutic target in colon cancer, where deregulation of the RAS/ERK pathway occurs at a very high frequency.